We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Visa, ExxonMobil Holdings and Pfizer
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 16, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. (V - Free Report) , ExxonMobil Holdings Corp. (XOM - Free Report) and Pfizer Inc. (PFE - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Visa, ExxonMobil & Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., ExxonMobil Holdings Corp.and Pfizer Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+28.4% vs. +10.5%). Per the Zacks analyst, the company benefits from its strong global brand, extensive payments network and growth in digital transactions, cross-border payments and commercial solutions. Investments in agentic commerce, stablecoin settlement and strategic acquisitions should further strengthen its competitive position.
However, rising client incentives and marketing expenses are pressuring profitability. Uneven cash activity across regions, elevated valuation and persistent regulatory and litigation risks remain concerns.
ExxonMobil’s shares have outperformed the Oil and Gas - Integrated - International industry over the past six months (+12.6% vs. +8.3%). The Zacks analyst believes that the company benefits from low-cost production, an integrated business model and expansion opportunities in the Permian, Guyana and global gas markets. Technological innovation, cost discipline and higher-value products strengthen efficiency and long-term competitiveness.
Yet, exposure to commodity price volatility and changing energy demand remains a concern. Large-scale project execution and the energy transition also pose operational and strategic challenges.
Pfizer’s shares have underperformed the Large Cap Pharmaceuticals industry over the past year (+22.8% vs. +33.7%). The Zacks analyst believes that the company faces significant patent expiration risks, while its near-term growth outlook remains subdued. Revenue pressure from losing exclusivity on key products could weigh on performance.
However, improving non-COVID product sales, new launches and acquisitions are supporting recovery. Pipeline investments in oncology and obesity offer longer-term growth opportunities, while its recent earnings surprise track record provides some encouragement.
Image: Bigstock
The Zacks Analyst Blog Highlights Visa, ExxonMobil Holdings and Pfizer
For Immediate Release
Chicago, IL – November 16, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. (V - Free Report) , ExxonMobil Holdings Corp. (XOM - Free Report) and Pfizer Inc. (PFE - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Visa, ExxonMobil & Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., ExxonMobil Holdings Corp.and Pfizer Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Today's Featured Research Reports
Visa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+28.4% vs. +10.5%). Per the Zacks analyst, the company benefits from its strong global brand, extensive payments network and growth in digital transactions, cross-border payments and commercial solutions. Investments in agentic commerce, stablecoin settlement and strategic acquisitions should further strengthen its competitive position.
However, rising client incentives and marketing expenses are pressuring profitability. Uneven cash activity across regions, elevated valuation and persistent regulatory and litigation risks remain concerns.
(You can read the full research report on Visa here >>>)
ExxonMobil’s shares have outperformed the Oil and Gas - Integrated - International industry over the past six months (+12.6% vs. +8.3%). The Zacks analyst believes that the company benefits from low-cost production, an integrated business model and expansion opportunities in the Permian, Guyana and global gas markets. Technological innovation, cost discipline and higher-value products strengthen efficiency and long-term competitiveness.
Yet, exposure to commodity price volatility and changing energy demand remains a concern. Large-scale project execution and the energy transition also pose operational and strategic challenges.
(You can read the full research report on ExxonMobil here >>>)
Pfizer’s shares have underperformed the Large Cap Pharmaceuticals industry over the past year (+22.8% vs. +33.7%). The Zacks analyst believes that the company faces significant patent expiration risks, while its near-term growth outlook remains subdued. Revenue pressure from losing exclusivity on key products could weigh on performance.
However, improving non-COVID product sales, new launches and acquisitions are supporting recovery. Pipeline investments in oncology and obesity offer longer-term growth opportunities, while its recent earnings surprise track record provides some encouragement.
(You can read the full research report on Pfizer here >>>)